Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
A phase 1/2 trial of TNG462 and Pembrolizumab in advanced solid tumours, run by Tango Therapeutics, Inc., now recruiting.
Overview
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors is a phase 1/2 interventional study registered as NCT05732831 by Tango Therapeutics, Inc., with 225 participants planned, started 2023-05-26 and due to reach its primary completion in 2027-06. Interventions recorded: TNG462 and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialS095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Shares TNG462, Tango Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.